A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Ovarian cancer
- Focus Diagnostic use; Registrational
- Sponsors On Target Laboratories
- 28 Aug 2019 Planned number of patients changed from 147 to 170.
- 28 Aug 2019 Planned End Date changed from 1 Nov 2019 to 1 May 2020.
- 28 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Apr 2020.